Meloxicam for oral administration
Patent 6869948 Issued on March 22, 2005. Estimated Expiration Date: 
March 26, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 26, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts thereof Water soluble salts of an NSAID with meglumine/glucamine Patent #: 4748174 InventorsAssigneeApplicationNo. 09277049 filed on 03/26/1999US Classes:514/226.5, One of the cyclos is a 1,2-thiazine (e.g.,1,2-benzothiazines, etc.)544/49Benzothiazines (including hydrogenated)ExaminersPrimary: Raymond, Richard L.Assistant: Truong, Tamthom N. Attorney, Agent or FirmForeign Patent References
International ClassesA61K031/54C07D279/16 AbstractThe invention relates in its first aspect to a rapidly decomposing tablet for pain therapy containing meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] in the form of a salt with an inorganic or organic base providing rapid absorption of the active substance, the process of its preparation by direct tabletting, and furthermore relates in a second aspect to the crystalline meloxicam meglumin salt mono- and dihydrate and the preparation thereof.Other References
|
| ||||||||||||||
